You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Carvedilol reduced mortality and morbidity caused by myocardial infarction in patients with left ventricular dysfunction

Article Text

Article menu
Download PDFPDF
Therapeutics
Carvedilol reduced mortality and morbidity caused by myocardial infarction in patients with left ventricular dysfunction

https://doi.org/10.1136/ebm.7.1.15

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Lancet 357, 1385. The CAPRICORN Investigators.. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.. May 5;. :. –90.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with left ventricular dysfunction, does adding carvedilol to the management of myocardial infarction (MI) reduce mortality and non-fatal MI?

    Design

    Randomised {allocation concealed*}†, blinded (patients, judicial assessors of outcomes, data analysts),* placebo controlled trial with a mean 1.3 years of follow up.

    Setting

    163 centres in 17 countries.

    Patients

    1959 patients (mean age 63 y, 74% men) participated. Inclusion criteria were age > 18 years; stable and definite MI occurring 3 to 21 days before randomisation; left ventricular ejection fraction ≤ 0.40; wall-motion-score index ≤ 1.3; current treatment with angiotensin-converting enzyme (ACE) inhibitors for ≥ 48 hours with a stable dose for ≥ 24 hours; and if the patient was having heart failure treatment with diuretics and …

    View Full Text

    Footnotes

    • Sources of funding: Glaxo SmithKline and Roche Pharmaceuticals.

    • For correspondence: Professor H J Dargie, Department of Cardiology, Western Infirmary, Glasgow G11 2NT, Scotland, UK. Fax +44 (0)141 211 1791.

    • ↵* See glossary.

    • ↵† Information provided by author.